News for Oncolytics Biotech Inc. (ONC.TO)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

PR NewswireVANCOUVER, BC, Feb. 27, 2025 USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US

PR NewswireSAN DIEGO and CALGARY, AB, Feb. 25, 2025 Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ETSAN DIEGO and CALGAR

PR NewswireSAN DIEGO and CALGARY, AB, Feb. 18, 2025 Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy

Significant Transaction on December 31, 2024 On December 31, 2024, Anson Funds Management LP (Trades, Portfolio) executed a noteworthy transaction by acquiring

PR NewswireSAN DIEGO and CALGARY, AB, Feb. 14, 2025 SAN DIEGO and CALGARY, AB, Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX:

PR NewswireSAN DIEGO and CALGARY, AB, Feb. 7, 2025 Search for Chief Executive Officer to commence immediatelySAN DIEGO and CALGARY, AB, Feb. 7, 2025 /PRNew

PR NewswireSAN DIEGO and CALGARY, AB, Jan. 15, 2025 New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1SAN DIEGO and

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the

Oncolytics Biotech ® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

PR NewswireSAN DIEGO and CALGARY, AB, Dec. 3, 2024 Early safety and tolerability results from six randomized patients support continued enrollment of pelar

Operator: Good afternoon and welcome to Oncolytics Biotech's Third Quarter 2024 Conference Call. All participants are in a listen-only mode.

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ETCompany ParticipantsJon Patton - Director of Investor...

Shares of Editas Medicine, Inc. (EDIT), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with

October 7, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including bi...

PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get...

Palm Beach, FL - March 5, 2024 (Investorideas.com Newswire) FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death glob...